GeneTex Incorporates Negative Controls into the Quality Assurance Process.
Antibodies are essential tools for both basic and clinical research. However, there has been growing distrust of commercially available antibodies with regard to specificity and performance variability. As a result, the research community and funding agencies have demanded that antibody suppliers increase their efforts to more thoroughly validate these reagents. One approach to address this is through knockout or knockdown of the target protein by CRISPR- or RNAi-mediated technologies.
Learn more about the CRISPR/Cas9 technology
Learn more about the knockdown technology
In support of this goal, GeneTex is conducting knockout/knockdown-based validation as a fundamental component of its antibody quality assurance process. To date, we have evaluated over four hundred of our most popular products covering multiple research topics, such as apoptosis, metabolism, epithelial–mesenchymal transition, and neurodegenerative diseases. We will continue to expand these efforts in the future. Antibodies that have passed the KO/KD test will be labeled with the KO/KD validated icon.
Share your KO/KD data with us!
If you want to share your knockout/knockdown validation data using GeneTex antibodies with us, please feel free to send us an email or contact us for further information. With your posted results, you will qualify for the GeneTex Rewards Program.
GeneTex cooperates with EdiGene to offer CRISPR knockout-validated antibodies
GeneTex is working with the genome editing company EdiGene to validate its antibodies through the integration of EdiGene's innovative CRISPR-based technology that produces gene-specific knockout (KO) cell lines. Lysates from these cell lines, conveniently generated in commonly used cells like HeLa and HEK293T, are used for western blot assays of GeneTex's antibody reagents. The goal of this combined effort is to assure researchers of the specificity of GeneTex's antibodies and the broad utility of KO cell lines from